- Home
- ARTV vs GNLX Comparison
ARTV vs GNLX Comparison
Compare ARTV & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARTV
- GNLX
- Stock Information
- Founded
- ARTV 2019
- GNLX 2001
- Country
- ARTV United States
- GNLX United States
- Employees
- ARTV N/A
- GNLX N/A
- Industry
- ARTV
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- ARTV
- GNLX Health Care
- Exchange
- ARTV NYSE
- GNLX Nasdaq
- Market Cap
- ARTV 186.1M
- GNLX 184.4M
- IPO Year
- ARTV 2024
- GNLX 2023
- Fundamental
- Price
- ARTV $3.77
- GNLX $4.81
- Analyst Decision
- ARTV Strong Buy
- GNLX Strong Buy
- Analyst Count
- ARTV 6
- GNLX 4
- Target Price
- ARTV $21.00
- GNLX $18.25
- AVG Volume (30 Days)
- ARTV 83.1K
- GNLX 331.4K
- Earning Date
- ARTV 03-04-2025
- GNLX 03-31-2025
- Dividend Yield
- ARTV N/A
- GNLX N/A
- EPS Growth
- ARTV N/A
- GNLX N/A
- EPS
- ARTV N/A
- GNLX N/A
- Revenue
- ARTV $2,601,000.00
- GNLX $8,000.00
- Revenue This Year
- ARTV N/A
- GNLX N/A
- Revenue Next Year
- ARTV N/A
- GNLX N/A
- P/E Ratio
- ARTV N/A
- GNLX N/A
- Revenue Growth
- ARTV N/A
- GNLX N/A
- 52 Week Low
- ARTV $3.37
- GNLX $1.60
- 52 Week High
- ARTV $17.31
- GNLX $8.67
- Technical
- Relative Strength Index (RSI)
- ARTV N/A
- GNLX 58.52
- Support Level
- ARTV N/A
- GNLX $4.62
- Resistance Level
- ARTV N/A
- GNLX $5.76
- Average True Range (ATR)
- ARTV 0.00
- GNLX 0.57
- MACD
- ARTV 0.00
- GNLX -0.03
- Stochastic Oscillator
- ARTV 0.00
- GNLX 59.96
About ARTV ARTIVA BIOTHERAPEUTICS INC
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.